The pharmacokinetics and safety of orally administered ciprofloxacin (Bay o 9867) were examined in 12 healthy male volunteers who received sequential doses of 250, 500, 750, and 1,000 mg. The individual and mean data were best described by biexponential disposition and elimination, assuming an apparent zero-order rate of absorption. The peak serum concentrations deterrmined from the individual data occurred at approximately 1.5 h after each dose and ranged from 0.42 to 4.2 ,ug/ml; the mean peak concentrations increased in proportion to the dose. The areas under the curve determined from the mean data were also proportional with respect to dose. The mean elimination half-lives calculated from pooled data were 4.1, 4.1, 6.9, and 6.3 h for doses of 250, 500, 750, and 1,000 mg, respectively. Longer half-lives but proportional area-under-the-curve values after the 750-and 1,000-mg doses implied that smaller fractions of ciprofloxacin were absorbed after these doses, although nonlinear kinetics could not be ruled out. The mean serum concentrations 12 and 24 h following each dose were -0.08 and 0.01 ,ug/ml, respectively. The urinary concentrations ranged from 30 to 500 ,ug/ml for at least 12 h after administration and were -9 ,ug/ml at 24 h following each dose. The urinary recovery level of unchanged ciprofloxacin over a 24-h period ranged from 28 to 44%. The mean renal clearances for each dose ranged from 300 to 500 ml/min. Ciprofloxacin was well tolerated, and no significant clinical or laboratory abnormalities were observed.
Ciprofloxacin (Bay o 9867), a new quinolone derivative that is chemically related to nalidixic acid and norfloxacin, is currently undergoing microbiologic, pharmacokinetic, and clinical evaluation. The MICs of ciprofloxacin for 90% of the Enterobacteriaceae, Pseuidomnonas aeruiiginiosa, Hatemo- philuis influenzae, Staphylococcus aureiis (including methicillin-resistant S. aiureuts), streptococcal, and Btacteroidesfragilis strains which have been tested including strains resistant to gentamicin and many third gei eration cephalosporins, range from 0.008 to 2.0 jig/ml (3, 6, 13) .
Ciprofloxacin was originally developed as an oral agent similar to nalidixic acid for the treatment of urinary tract infections. However, due to its excellent activity against gram-negative bacteria, development of a parenteral product is currently underway for use in the treatment of systemic bacterial infections. The purpose of this study was to determine the pharmacokinetic disposition and tolerance of orally administered ciprofloxacin in healthy volunteers after sequential increasing doses.
MATERIALS AND METHODS
Sixteen healthy males (ages 22 to 26 years) were randomly selected to receive either ciprofloxacin (12 subjects) or a placebo (4 subjects). Before the study and before each of the four weekly doses, all of the subjects underwent physical examinations, including electrocardiograms, complete blood counts, platelet counts, a panel of 20 serum chemistry tests, urinalysis, and a stool test for occult blood. Another examination was performed 24 h after each dose.
Ciprofloxacin was given in the form of 250-mg tablets as a single dose once a week for 4 weeks (250, 500, 750, and 1,000 * Corresponding author. mg). The subjects fasted starting at midnight and were given the tablet(s) with 240 ml of water at 8:00 a.m. The subjects remained fasting until noon. Blood and urine samples for drug assays were collected for 48 h after ingestion of the drug.
Analytical methods. (i) Microbiological assay. The bioassays were performed by standard procedures, using a modification of a procedure provided by Miles Pharmaceuticals (10) . A susceptible isolate of Klebsiella pnieuimoniae (strain ATCC 10031) was used as the indicator organism. The sensitivity of the assay was 0.02 ,ug/ml. The reproducibility and accuracy of the assay were demonstrated by determining mean zone diameters (n = 8) at the extremes of the calibration curve; at 0.02 and 1.62 ,ug/ml, the coefficients of variation were 3.79 and 2.96%, respectively. According to Miles Pharmaceuticals, bioassay results have been shown to correlate very well with high-pressure liquid chromatography results.
(ii) Pharmacokinetic analysis. When graphs of the logarithm of ciprofloxacin concentration versus time were examined, a biexponential decline was observed for serum levels after the peak. The CSTRIP computer program (12) was used to obtain initial estimates, and the NONLIN nonlinear regression progam (11) was used to fit the first-order equation to the data. Weights of the inverse of the concentration were used for the individual data, and weights of the inverse of the variance were used for the mean data. It was obvious that a first-order model, including introduction of a lag phase, did not fit the absorption phase and, in particular, the peak of the concentration-time curve.
Consequently, a zero-order model was fit to the data by using the NONLIN program and weights as described previously, and comparisons were made with the previous fits.
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The following parameters were determined by the fitting procedure: T, koFIVC, Xl, X2, and k2l, where T was the apparent duration of absorption, ko was the apparent zeroorder rate of absorption, F was the fraction of the dose absorbed, V, was the volume of the central compartment, K1
was the distribution rate constant, X2 was the terminal disposition rate constant, and k21 was an intercompartmental ,rate constant. The ciprofloxacin levels (C) as a function of time (t) could best be described by the following equation (7):
where during absorption T was equal to t and varied with time. After absorption ceased, T became the constant corresponding to the apparent duration-of absorption. The elimination half-life was calculated from the natural logarithm of 2 divided by _Y2. The areas under the curve (AUC) --were determined by using a trapezoidal rule for observed data corrected to include the area from the last serum level to infinity. The other intercompartmental rate constants (K12 and k1o) were calculated from the following equations: k1o = X1X2/k21 and k12 = k1 + \2 -k2l -k1o. (iii) Statistical analyses. The mean pharmacokinetic parameters for the four treatments were compared for statistical variation by using one-way analysis of variance methods. Sigfiificant differences were reported by using Tukey's studentized range (HSD) test.
RESULTS
The mean serum concentrations after each ciprofloxacin dose are shown in Fig. 1 . Our initial analysis (twocompartment model and first-order absorption) did not provide a good fit between the observed and estimated concentrations, whereas analysis with an apparent zero-order rate of absorption significantly improved the fit for all doses (Fig.  2 ). The pharmacokinetic parameters described below were estimated from a two-compartment model by assuming apparent zero-order absorption ( Table 1) .
The observed peak serum concentrations (Cmax) determined from individual data ranged from 0.42 to 4.2 ,ug/ml and occurred by 2 h after administration. There was great intersubject variability for Cmax after each dose; however, no statistical differences were found when the mean Cmax were corrected for dose. There was also no statistical differences among the mean AUC values corrected for dose. Therefore, we observed that the mean Cmax and AUC values increased proportionally with increasing doses. The extent of absorption appeared to be directly related to dose.
The mean terminal half-lives were 4.1, 4.1, 6.9, and 6.3 h for doses of 250, 500, 750, and 1,000 mg, respectively. The terminal elimination rate constants after the 250-and 500-mg doses were significantly different from those after the 750-and 1,000-mg doses (P. < 0.0001).
The mean serum concentrations at 12 and 24 h after treatment were approximately .0.08 and 0.01 ,ug/ml, respectively. The mean urinary concentrations for each dose over a 48-h period are shown in Fig. 3 . Through 12 h, the urine concentrations were .30 ,ug/ml after all doses. At 24 and 48 h, the urine concentrations were generally -1.0 ,ug/ml. The mean b n is the number of subjects in each adalysis. Two subjects were excluded from the mean 250-mg dose analysis because their individual data were best fit with a one-compartment model, assuming an apparent zero-order rate of absorption. Another subject was also eliminated from the 250-mg dose mean analysis because his serum levels during a significant portion of the terminal phase were below the limits of the assay. Finally, one subject was excluded from all mean analyses because a good fit was not obtained with either of the pharmacokinetic models employed. a CLR values are expressed as means ± standard deviations; n = 12, except where indicated otherwise. bn= 11. ' For the 250-mg dose there were statistically significant differences between the values for the 2-to 4-h interval and the 12-to 16-h interval (P = 0.0001) and between the values for the 2-to 4-h interval and the 16-to 24-h interval (P = 0.0001). For the 500-mg dose, the value for the 2-to 4-h interval and the value for the 12-to 16-h interval were also significantly different (P = 0.0001).
d n = 6. e = 7.
unknown, ko and V, could not be determined separately.
Thus, the expression koFIVc was estimated; the mean values were similar for the 250-and 500-mg doses, whereas the values after the 750-and 1,000-mg doses appeared to be larger, although only the values after the 250-and 1,000-mg doses were significantly different (P < 0.04) ( Table 1) . No adverse reactions (e.g., gastrointestinal disturbances, headaches, vision problems, dizziness, rash, etc.) or abnormalities in laboratory tests were observed during the study period.
DISCUSSION
This study revealed several significant properties of the disposition of ciprofloxacin after sequential increasing oral doses. Although the absorption phase of our data was best fit by a zero-order equation, it may be events leading up to the absorption step which are rate limiting, thus forcing the absorption to appear to be zero order. The gastrointestinal absorption data for other antibiotics, including sulfisoxazole, griseofulvin, and erythromycin, have been described by a zero-order process and were likely due to dissolution problems (2, 4, 9) . However, we have no evidence to suggest that ciprofloxacin has dissolution problems because peak serum concentrations were attained rapidly and were consistent. Furthermore, ciprofloxacin is an amphoteric drug and is probably absorbed by passive diffusion. Intestinal pH changes suggest that rapid absorption may occur in the duodenum and proximal jejunum, whereas absorption may decrease in the distal portion of the intestine.
Maximal serum concentrations were observed 2 h after drug administration and were at least two to four times the MIC for 90% of the strains tested for most organisms in the Enterobacteriaceae. The mean Cmaxs after the 500-and 250-mg doses were similar to values reported by Crump et al. (5) and Arnoff et al. (1), respectively. In contrast, Gonzalez et al. (8) reported CmaxS that were higher than our values after single doses of 250, 500, and 750 mg. Our mean Cmax and AUC values increased in proportion to dose.
Elimination of ciprofloxacin was observed to be biexponential, with the mean terminal half-life ranging from 4 to 7 h. After a single 250-mg dose, an elimination half-life of 3.7 ± 0.9 h has been reported (1). Crump et al. observed a mean half-life of 3.9 ± 0.8 h after a single 500-mg dose (5). Mean half-lives of 4.2 and 4.9 h have been reported after single 250-and 500-mg doses, respectively (8) . After a single 100-mg intravenous bolus injection, the mean elimination half-life was 4.0 ± 0.9 h (14). These results are consistent with our findings for 250-and 500-mg doses. Of more interest is the noticeable trend of increasing half-life with increasing dose (Fig. 1) . There is some suggestion of this observation in the data of Gonzalez et al., who found that the half-life was longer after a single 750-mg dose, as well as after multiple doses (8) . Arnoff and co-workers reported an increase in half-life from 3.7 to 6.5 h after 13 250-mg doses (1). Thus, it appears that elimination of ciprofloxacin may be nonlinear. Another explanation for the apparent increased half-life is a slow continuous absorption phase due to pH-dependent phenomena.
For each subject we made six estimates of CLR for each dose. We observed that the CLR greatly exceeded the glomerular filtration rate in all cases; thus, tubular secretion must be a pathway of elimination. Wise et al. reported a mean CLR value of 479 + 68.2 ml/min after an intravenous dose (14) . This is in agreement with our data. Variability in CLR was also observed by Wise and his colleagues (14) . We analyzed the urine data of these workers, calculated the CLR for each collection interval, and found that the CLR was highly variable among the collection intervals. Our mean CLR appeared to decrease with the 1,000-mg dose; in addition, the mean urine concentrations after the 1,000-mg dose were generally lower than those after the 750-mg dose. Saturation of a tubular secretion pathway may have occurred with the 1,000-mg dose, although our data are too variable to prove this.
An increase in elimination half-life should greatly increase the AUC. However, we found no difference in the AUC corrected for dose with the750-and 1,000-mg treatments. A decreased fraction absorbed with the higher doses may be an explanation for this inconsistency. This hypothesis is supported by our urinary recovery (U0O48) data.
Urine concentrations exceed the MIC for 90% of the strains tested for most urinary tract pathogens; preliminary dosing recommendations are 250 to 500 mg every 24 to 48 h. Treatment of systemic infections with ciprofloxacin will probably necessitate the use of a parenteral dose form. However, a dosage interval of 24 h for treatment of mild to moderate infections seems appropriate, whereas lifethreatening infections may require more frequent administration (e.g., every 12 h).
Recently, ciprofloxacin has been shown to have four active metabolites, which were isolated from the urine and accounted for 15% of the administered dose (Proc. Ciprofloxacin Workshop, Tokyo, Japan, 1984). It is possible that some of our conclusions regarding the disposition of ciprofloxacin may be erroneous, although excellent correlations between bioassay and high-pressure liquid chromatography results have been documented (Miles Pharmaceuticals). Determination of the metabolic fate of ciprofloxacin will facilitate our understanding of its disposition. 
